AKRX has been the subject of a number of other research reports. BidaskClub downgraded shares of Akorn from a strong-buy rating to a buy rating in a report on Tuesday, August 28th. Deutsche Bank reaffirmed a buy rating on shares of Akorn in a report on Thursday, August 23rd. Piper Jaffray Companies set a $5.00 price objective on shares of Akorn and gave the stock a hold rating in a report on Tuesday, October 2nd. ValuEngine raised shares of Akorn from a sell rating to a hold rating in a report on Tuesday, October 2nd. Finally, Jefferies Financial Group decreased their price objective on shares of Akorn to $6.00 and set a hold rating for the company in a report on Wednesday, October 3rd. Four investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $14.67.
Shares of AKRX stock traded down $0.02 during mid-day trading on Wednesday, reaching $6.85. 2,929,630 shares of the company were exchanged, compared to its average volume of 4,226,315. Akorn has a fifty-two week low of $5.25 and a fifty-two week high of $33.63. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.47 and a quick ratio of 2.87.
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Read More: Treasury Bonds
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.